AstraZeneca PLC (AZN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AstraZeneca PLC (AZN) Healthcare & Pipeline Overview

AstraZeneca PLC is a global biopharmaceutical leader specializing in prescription medicines across oncology, cardiovascular, renal, and metabolic diseases. With a strong focus on innovation and strategic collaborations, AstraZeneca serves primary and specialty care physicians worldwide, maintaining a robust pipeline of novel therapies and a diverse portfolio of established products.

What Is the Investment Thesis for AZN?

The company's focus on key therapeutic areas like oncology, cardiovascular, and renal diseases positions it to capitalize on growing healthcare needs. With a profit margin of 17.2% and a gross margin of 79.7%, AstraZeneca demonstrates strong financial performance. Upcoming data readouts from its clinical trials and potential regulatory approvals could serve as significant catalysts. However, investors should be aware of potential risks, including patent expirations and competition from biosimilars. The company's beta of 0.28 suggests relatively low volatility compared to the broader market.

Based on FMP financials and quantitative analysis

AZN Key Highlights

Market capitalization of $245B reflects AstraZeneca's significant presence and valuation in the global pharmaceutical market.

• P/E ratio of 23.85 indicates investor expectations for future earnings growth relative to current profitability.
• Gross margin of 79.7% showcases AstraZeneca's ability to maintain high profitability on its product sales.
• Dividend yield of 1.77% provides a steady income stream for investors, enhancing the stock's attractiveness.
• AstraZeneca's strategic collaborations with companies like Neurimmune AG and BenevolentAI highlight its commitment to innovation and drug discovery.

Who Are AZN's Competitors?

AZN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AZN's Key Strengths?

Strong portfolio of established pharmaceutical products.

• Robust pipeline of innovative therapies in development.
• Global presence and distribution network.
• Strategic collaborations and partnerships.

What Are AZN's Weaknesses?

Reliance on key products with patent expirations.

• Exposure to regulatory risks and challenges.
• Dependence on successful clinical trial outcomes.
• Competition from generic and biosimilar products.

What Could Drive AZN Stock Higher?

Clinical trial results for new oncology therapies in Q3 2026.

• Regulatory approval decisions for key pipeline drugs in H2 2026.
• Expansion of existing product indications to new patient populations.
• Strategic collaborations and partnerships to enhance drug discovery and development.
• Increasing demand for AstraZeneca's products in emerging markets.

What Are the Key Risks for AZN?

Insider selling — insiders were net sellers of roughly $2.2M recently.

• Patent expirations on key products leading to generic competition.
• Unfavorable clinical trial results impacting pipeline development.
• Regulatory challenges and pricing pressures in key markets.
• Competition from other pharmaceutical companies.
• Currency fluctuations affecting revenue and profitability.

What Are the Growth Opportunities for AZN?

• Expansion in Oncology: AstraZeneca has a significant opportunity to grow its oncology franchise, driven by innovative therapies like Tagrisso, Imfinzi, and Enhertu. The global oncology market is projected to reach $373.5 billion by 2030, presenting a substantial growth avenue. AstraZeneca's focus on targeted therapies and immuno-oncology positions it well to capture a larger market share through ongoing clinical trials and new product launches.
• Cardiovascular and Renal Disease Treatments: AstraZeneca's portfolio in cardiovascular and renal diseases, including Farxiga and Lokelma, offers significant growth potential. The increasing prevalence of diabetes and chronic kidney disease is driving demand for innovative treatments. The global market for cardiovascular drugs is expected to reach $165 billion by 2027. AstraZeneca can leverage its established presence and pipeline to address these growing needs.
• Rare Disease Portfolio Expansion: AstraZeneca's acquisition of Alexion Pharmaceuticals has strengthened its rare disease portfolio, with products like Soliris and Ultomiris. The rare disease market is characterized by high unmet needs and premium pricing. The global rare disease market is projected to reach $258.7 billion by 2030. AstraZeneca can drive growth by expanding the indications for existing products and developing new therapies for rare diseases.
• Strategic Collaborations and AI-Driven Drug Discovery: AstraZeneca's collaborations with companies like BenevolentAI and Absci Corporation in AI-driven drug discovery can accelerate the development of novel therapies. AI and machine learning are transforming drug discovery by improving efficiency and reducing development costs. These collaborations can lead to the identification of new drug targets and the development of more effective treatments, providing a competitive edge.
• Emerging Markets Growth: AstraZeneca has the opportunity to expand its presence in emerging markets, where healthcare spending is increasing rapidly. These markets offer significant growth potential due to rising incomes and improved access to healthcare. AstraZeneca can leverage its established infrastructure and partnerships to commercialize its products in these regions, contributing to overall revenue growth. Focus on markets in Asia and Africa could yield significant returns.

What Are AZN's Competitive Advantages?

• Patent protection for key pharmaceutical products.
• Strong brand recognition and reputation in the healthcare industry.
• Extensive global distribution network.
• Robust research and development capabilities.
• Strategic collaborations and partnerships.

What Does AZN Do?

AstraZeneca PLC, founded in 1992 and headquartered in Cambridge, UK, emerged from the merger of Astra AB and Zeneca Group PLC in 1999. The company is dedicated to the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca's portfolio includes well-known brands such as Tagrisso, Imfinzi, Lynparza, and Farxiga, targeting therapeutic areas including oncology, cardiovascular, renal, and metabolism. The company also offers treatments for respiratory diseases and rare conditions. AstraZeneca serves healthcare providers and patients across the globe, with a significant presence in the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia. Its global operations are supported by a network of distributors and local representative offices. AstraZeneca fosters innovation through strategic collaborations, such as partnerships with Neurimmune AG, BenevolentAI, Lunit, and Absci Corporation, focusing on drug discovery and development in areas like systemic lupus erythematosus and oncology. With a workforce of over 94,300 employees, AstraZeneca continues to expand its reach and impact in the biopharmaceutical industry, driven by a commitment to scientific advancement and patient care.

What Products and Services Does AZN Offer?

• Discovers and develops prescription medicines.
• Manufactures pharmaceutical products.
• Commercializes and markets drugs globally.
• Focuses on therapeutic areas including oncology, cardiovascular, renal, and metabolism.
• Offers treatments for respiratory diseases and rare conditions.
• Engages in strategic collaborations for drug discovery and development.
• Serves primary care and specialty care physicians through distributors and local offices.

How Does AZN Make Money?

• Develops and patents innovative prescription medicines.
• Generates revenue through the sale of branded pharmaceutical products.
• Partners with distributors and local representatives for global market access.
• Invests in research and development to expand its product pipeline.

What Industry Does AZN Operate In?

AstraZeneca PLC operates in the highly competitive pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The global pharmaceutical market is experiencing growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. AstraZeneca competes with major players such as Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Novartis AG (NVS), and Merck & Co., Inc. (MRK). The company's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products.

Who Are AZN's Key Customers?

• Primary care physicians
• Specialty care physicians
• Hospitals and clinics
• Patients requiring prescription medications
• Healthcare providers in various therapeutic areas

Over the past six months, AstraZeneca PLC insiders filed 6 SEC Form 4 transactions — 1 sales and 5 purchases. On net that is roughly 12K shares disposed (about $2.2M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: AstraZeneca PLC

Revenue for AstraZeneca PLC came in at $15.38B during Q2 FY2026. The company recorded net income of $2.51B, with diluted EPS of $1.61. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, AZN averaged $1.67 in diluted EPS.

AZN Valuation & Market Position

With a $245B market cap, AstraZeneca PLC sits in the mega-cap segment of the market. Analyst price targets span from $158.00 to $216.00, with a consensus of $186.67. At the current price of $157.88, that implies approximately 18% upside potential. Relative to its peer group, AZN's quantitative score of 85/100 is roughly in line with the peer average of 77/100.

Return on equity for AstraZeneca PLC stands at 22.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.2%, showing how much profit it generates from its asset base. AZN trades at a trailing price-to-earnings ratio of 23.85, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.

AstraZeneca PLC's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.29 places it in the safe zone, indicating low near-term bankruptcy risk.

AstraZeneca PLC has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.6% above estimates on average.

Company Profile

AstraZeneca PLC operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Cambridge, GB. The company is led by CEO Pascal Claude Roland Soriot. AZN has traded publicly since 1993.

AZN Financials

AZN Latest News

AZN Analyst Consensus

AZN MoonshotScore

Latest AstraZeneca PLC Analysis

AstraZeneca PLC Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources